ABOS

NASDAQ open

Acumen Pharmaceuticals

0.17 USD
▼-0.02-12.42%
盘后 0.21 0.00%
2026-11-20
市值
$13.49M
市盈率
—
EPS
-1.55
股息率
—
52 周区间
0.16 – 3.60
成交量
632.62K
Beta
0.45
目标价
1.00
52W 低 0.1652W 高 3.60
价格走势

公司简介

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development o...